SFCM
IKT icon

Seven Fleet Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Seven Fleet Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$547K Sell
325,600
-208,048
-39% -$369K 0.17% 79
2025
Q4 		$1.09M Buy
+533,648
New +$849K 0.74% 25

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Seven Fleet Capital Management's IKT Position: Q1 2026 in Review

Seven Fleet Capital Management reduced its Inhibikase Therapeutics (IKT) stake by 39% in Q1 2026, selling an estimated $369K and leaving 325,600 shares worth $547K. The position accounts for 0.17% of the portfolio, ranked #79.

Seven Fleet Capital Management first reported a position in IKT in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.09M in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Seven Fleet Capital Management held 325,600 shares of Inhibikase Therapeutics worth $547K as of Q1 2026.
  • Seven Fleet Capital Management sold 208,048 Inhibikase Therapeutics shares in Q1 2026, an estimated $369K.
  • Inhibikase Therapeutics made up 0.17% of Seven Fleet Capital Management's portfolio in Q1 2026, its #79 holding.
  • Seven Fleet Capital Management first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Seven Fleet Capital Management's Inhibikase Therapeutics position peaked at $1.09M in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.